Sep 21, 2020 / 08:00PM GMT
Operator
My name is Erica, and I will be your conference facilitator today for Amgen's conference call in conjunction with the ESMO 2020 virtual congress. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. (Operator Instructions)
I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin.
Arvind Sood - Amgen Inc. - VP of IR
Thank you, Erica. Good afternoon, everybody. Thank you for joining us 2 days in a row here. So we presented some important data earlier today in the virtual scientific sessions of ESMO. On our extended half-life BiTE AMG 160 that targets PSMA or prostate-specific membrane antigen. Our BiTE platform is an off-the-shelf clinically validated immuno-oncology platform, and we are advancing several BiTE constructs against high-quality targets in solid tumors and hematologic malignancies.
To further discuss this platform as well as the AMG 160 data presented today, I'm joined today by Dr. David Reese,
Amgen Inc AMG 160 Update Call from ESMO Virtual Congress 2020 Transcript
Sep 22, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers